EMA accelerates Gilead HCV drug
This article was originally published in Scrip
Executive Summary
Gilead Sciences hopes to launch sofosbuvir for chronic hepatitis C virus (HCV) infection in the first half of 2014 in Europe after the European Medicines Agency (EMA) accepted the firm's marketing authorization application (MAA) for the drug, and granted it an accelerated review.